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MaBACKGROUND At the end of 2 previous trials, an excess of stroke and bleeding was observed in patients with AF
randomized to a new oral anticoagulant (NOAC) who transitioned to a vitamin K antagonist (VKA).
OBJECTIVES The ENGAGE AF–TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation—
Thrombolysis in Myocardial Infarction 48) trial compared once-daily edoxaban to warfarin for stroke prevention in pa-
tients with AF. An end-of-trial transition plan was developed to minimize the risks of stroke due to inadequate antico-
agulation and bleeding from excessive anticoagulation during this critical period.
METHODS All patients on the blinded study drug at the trial’s conclusion were included in this analysis. In pre-speciﬁed
analyses, stroke, bleeding, and death that occurred through 30 days after the end-of-trial visit were stratiﬁed by ran-
domized treatment allocation and open-label anticoagulant selected post-trial.
RESULTS Of the 13,642 patients taking the blinded study drug at the end of the trial, 9,304 (68.2%) were transitioned
to open-label VKA and 4,258 patients (31.2%) to an NOAC. There were 21 strokes evenly distributed across the 3 ran-
domized treatment arms: warfarin 7 (1.90%/year), edoxaban high dose 7 (1.89%/year), edoxaban low dose 7 (1.85%/
year). Major bleeding was also similar across the 3 treatment arms: warfarin 11 (2.98%/year), edoxaban high dose 10
(2.69%/year), edoxaban low dose 18 (4.76%/year). In patients transitioned to VKA, 85% of patients had at least 1
INR $2 by day 14 after the transition and 99% by day 30.
CONCLUSIONS The ENGAGE AF–TIMI 48 transition plan protected patients from an excess of thrombotic and
bleeding events and should be helpful in clinical practice when patients are transitioned between oral anticoagulants.
(Global Study to Assess the Safety and Effectiveness of Edoxaban [DU-176b] vs Standard Practice of Dosing With
Warfarin in Patients With Atrial Fibrillation [EngageAFTIMI48]; NCT00781391) (J Am Coll Cardiol 2014;64:576–84)
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ABB R E V I A T I O N S
AND ACRONYMS
AF = atrial ﬁbrillation
factor Xa = activated factor X
INR = international normalized
ratio
NOAC = new oral
anticoagulant
SEE = systemic embolic event
TIMI = thrombolysis in
myocardial infarction
VKA = vitamin K antagonist
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577A trial ﬁbrillation (AF) predisposes patients toan increased risk of embolic stroke and isassociated with a higher mortality rate than
sinus rhythm (1–3). Warfarin and other vitamin K
antagonists (VKAs) are highly effective in preventing
stroke, but limited by their narrow therapeutic win-
dow and inconveniences imposed by the need for
coagulation monitoring and frequent dose adjust-
ments (4–6).
Four new oral anticoagulants (NOACs) that inhibit
thrombin or activated factor X (factor Xa) in a dose-
dependent fashion and do not require regular moni-
toring have been found to be at least as effective and
safe as warfarin for preventing stroke and systemic
embolic events (SEE) in patients with AF in their
respective phase 3 trials (7–10). In the 2 previous trialsSEE PAGE 585investigating factor Xa inhibitors, the ROCKET AF
(Rivaroxaban Once daily oral direct factor Xa inhibi-
tion Compared with vitamin K antagonism for pre-
vention of stroke and Embolism Trial in Atrial
Fibrillation) (11) and ARISTOTLE (Apixaban for Re-
duction In STroke and Other Thromboembolic Events
in Atrial Fibrillation) (12) trials, there was an excess of
both thrombotic and bleeding events in the 30 days
after the end of the trial when patients were transi-
tioned from the blinded study drug to open-label
antithrombotic therapy.
In the ROCKET AF trial, there was a more than
3-fold increase in stroke or SEE (blinded rivaroxaban
to open-label VKA: 22 events [6.42%/year] vs. blinded
warfarin to open-label VKA: 6 events [1.73%/year])
and major bleeding (blinded rivaroxaban to open-
label VKA: 25 events [7.29%/year] vs. blinded war-
farin to open-label VKA: 7 events [2.01%/year]) in
patients randomized to rivaroxaban compared with
warfarin who transitioned to open-label VKA at
the end of the trial (11). In the ARISTOTLE trial,
a 2-day bridging period with apixaban (in patients
randomized to apixaban) or placebo (in patients ran-
domized to warfarin) in addition to open-label VKA
was employed to mitigate the increased risk of stroke.
However, an excess of thrombotic (stroke or SEE:
blinded apixaban to open-label VKA: 21 events
[4.02%/year] vs. blinded warfarin to open-label VKA:
5 events [0.99%/year]) and major bleeding (blinded
apixaban to open-label VKA: 26 events [4.97%/year]
vs. blinded warfarin to open-label VKA: 10 events
[1.97%/year]) were seen in the 30-day period after the
trial in patients randomized to apixaban compared
with warfarin (12). Events after the end of the open-
label RE-LY (Randomized Evaluation of Long-Term
Anticoagulation Therapy) trial were not reported, andselected patients still on dabigatran at the
completion of the trial were eligible to
continue dabigatran as part of a long-term,
open-label extension study (RELY-ABLE
[Long-term Multicenter Extension of Dabiga-
tran Treatment in Patients with Atrial Fibril-
lation]) (7,13). The U.S. Food and Drug
Administration has issued a “boxed warning”
in the prescribing information for dabigatran,
rivaroxaban, and apixaban, cautioning pro-
viders that discontinuation of therapy could
increase the risk of thrombotic events (14–16).
The ENGAGE-AF-TIMI 48 trial (Effective
Anticoagulation with Factor Xa Next Generation
in Atrial Fibrillation—Thrombolysis in Myocardial
Infarction 48) was a randomized, double-blind, dou-
ble-dummy trial comparing 2 once-daily edoxaban
dose-regimens of warfarin in 21,105 patients with AF
at moderate to high risk of stroke (10,17). Prior to trial
completion, a transition plan was developed to pro-
tect patients transitioning to open-label VKA or an
NOAC at the trial’s end by minimizing both the risk of
ischemic stroke due to inadequate anticoagulation
and the risk of bleeding with excessive anti-
coagulation while maintaining the integrity of the
blinding to the treatment allocation. This was the ﬁrst
trial with a robust experience of patients transition-
ing to an open-label NOAC (n ¼ 4,258) and provides
information on the efﬁcacy and safety of transitions
between all available anticoagulants: VKA to all 3
approved NOACs (dabigatran, rivaroxaban, apixaban)
and edoxaban to VKA or 1 of the 3 other NOACs.
We hypothesized that a comprehensive transition
plan described below would protect patients tran-
sitioning from blinded to open-label anticoagulation
at the end of the trial by minimizing both the risk
of ischemic stroke due to inadequate anticoagu-
lation and the risk of bleeding with excessive
anticoagulation. Evidence-based guidance is needed
in this area as patients in clinical practice are
frequently switched from 1 anticoagulant to another
before and after procedures when they develop
side effects from a particular anticoagulant or need
to switch due to changes in insurance coverage
or are prescribed a necessary, but contraindicated,
medication.
METHODS
STUDY POPULATION. The ENGAGE AF–TIMI 48 trial
has been described previously (17). Eligible patients
were $21 years of age with AF documented on an
electrical tracing within 12 months, a CHADS2 risk
score $2, and anticoagulation planned for the trial
TABLE 1 Baseline Ch
Character
Age, yrs
Age $75 yrs, %
Female, %
Region, %
North America
Latin America
Western Europe
Eastern Europe
Asia-Paciﬁc and Sout
AF type, %
Paroxysmal
Persistent
Permanent
CHADS2 score (mean)
#3, %
4–6, %
Previous stroke or TIA,
Heart failure, %
Diabetes, %
Hypertension, %
Prior myocardial infarc
VKA experienced, %
Dose reduction at rand
Medications at time of
Aspirin
Thienopyridine
Amiodarone
Digoxin or digitalis
preparation
Values are median (interq
weight 60 kg or less, as w
verapamil or quinidine at r
exposure to the patients w
adjustment.
AF ¼ atrial ﬁbrillation;
congestive heart failure (C
stroke or transient ischemi
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578duration. Patients were randomly assigned (1:1:1) to
receive warfarin, dose-adjusted to an international
normalized ratio (INR) of 2.0 to 3.0, high-dose edox-
aban (60 mg once daily) or low-dose edoxaban
(30 mg once daily). The dose of edoxaban was reduced
by half, if any of the following were present at
randomization or during the course of the trial:
creatinine clearance 30 to 50 ml/min; body weight
# 60 kg; or concomitant verapamil, quinidine, or
dronaderone (potent P-glycoprotein inhibitors). To
be eligible for the transition plan and to be included
in this analysis, patients had to have been on a
blinded study drug within 3 days of their end-of-trial
visit. Patients off the study drug for >3 days werearacteristics
istic
All Patients
Randomized
(N ¼ 21,105)
Patients on Study Drug at End of Trial
Warfarin
(n ¼ 4,503)
Edoxaban
High Dose
(n ¼ 4,526)
Edoxaban
Low Dose
(n ¼ 4,613)
72 (64–78) 70 (63–76) 71 (63–76) 71 (63–77)
40.2 34.0 34.3 35.6
38.1 36.8 36.0 37.9
22.2 20.0 19.5 19.3
12.6 11.9 12.4 12.4
15.3 14.5 14.4 14.5
33.8 37.5 37.3 37.2
h Africa 16.0 16.1 16.3 16.6
25.4 25.0 24.6 25.7
23.1 22.8 22.8 22.6
51.5 52.3 52.6 51.7
2.8 2.8 2.8 2.8
77.4 79.5 79.3 79.4
22.6 20.5 20.7 20.6
% 28.3 28.0 27.9 28.2
57.4 57.1 58.2 56.0
36.1 35.8 35.8 36.6
93.6 94.1 93.7 94.1
tion, % 11.5 10.3 10.1 10.7
58.9 60.8 59.3 60
omization*, % 25.4 20.4 20.7 21.1
randomization, %
29.3 27.6 28.3 28.1
2.3 1.8 2.1 1.9
11.8 11.7 12.0 11.4
30.0 29.8 28.9 28.5
uartile range) or n (%). *Patients with a creatinine clearance #50 ml/min or body
ell as patients who were receiving the concomitant strong P-glycoprotein inhibitors
andomization, received a 50% reduction in the dose of edoxaban to maintain similar
ho did not have any of these 3 factors. Some patients had more than 1 reason for dose
CHADS2 ¼ stroke risk factor scoring system where 1 point is given for history of
), hypertension (H), age $75 years (A), diabetes (D), and 2 points given for history of
c attack (S); TIA ¼ transient ischemic attack; VKA ¼ vitamin K antagonist.encouraged to resume anticoagulation as clinically
indicated but were not included in this analysis,
as they were not therapeutically anticoagulated at
their end-of-trial visit and did not require a
transition from the blinded study drug to open-label
anticoagulation.
END-OF-TRIAL TRANSITION PLAN. The end-of-trial
transition plan consisted of 4 key components: 1)
selection of the oral anticoagulant (VKA or an NOAC)
by the treating physician and patient; 2) a 14-day
transition kit of modiﬁed-dose edoxaban for pa-
tients randomized to edoxaban (30 mg once daily for
patients in whom the edoxaban dose was not reduced
before the end-of-trial visit and 15 mg once daily for
patients in whom the edoxaban dose had been
reduced before the end-of-trial visit, regardless of
randomized edoxaban drug assignment) or matching
placebo for patients randomized to warfarin (Online
Table 1); 3) early and frequent INR testing ($3 tests
during the ﬁrst 2 weeks); and 4) use of a VKA titration
algorithm.
At the end-of-trial visit, INR was measured with
a point-of-care device and a prescription for the
intended open-label anticoagulant (VKA or NOAC)
was provided. The transition kit was provided only to
patients who were transitioning to open-label VKA
and was continued until an open-label INR $2 was
achieved or until day 14 (whichever occurred ﬁrst). If
the INR was <2.0 during the transition period, the
patient continued on the transition kit (up to 14 days)
with aggressive titration of open-label VKA dose as
recommended by the protocol algorithm (Online
Table 2). INR measurements were mandated at days
4 to 6, 7 to 10, and 11 to 14 and as often as needed
through day 30 until the patient was conﬁrmed to be
in therapeutic range. Open-label INR testing was not
allowed on days 1 to 3 to avoid unblinding so as to
maintain the integrity of the trial.
Patients transitioning to an NOAC were not given
a transition kit (active edoxaban or matching pla-
cebo). If the INR was <2.0 at the end-of-trial visit, the
patient was started on an open-label NOAC the
following day and if the INR was $2.0 the patient
returned for an open-label INR measurement on days
4 to 6 (and every 1 to 4 days thereafter, if necessary),
until the INR was <2.0, at which time the open-label
NOAC was begun on the same day. All patients were
followed for a minimum of 30 days after their end-of-
trial visit.
STATISTICAL ANALYSIS. Evaluation of the efﬁcacy
and safety at the end-of-study transition plan in
the ENGAGE AF–TIMI 48 trial was pre-speciﬁed.
Descriptive statistics of baseline characteristics were
13,642 Patients on Study Drug at the End of the Trial
Warfarin*
N=4503
Placebo
VKA VKA VKADabigatran Oral Fxa Dabigatran Oral Fxa Dabigatran Oral Fxa
N=3,147 N=659 N=669 N=3,050 N=3,107N=722 N=723 N=759 N=726
No Kit
Used
N=9
No Kit
Used
N=9
No Kit
Used
N=5
Placebo
(Dose Adj)
N=840
Edox 15
(Dose Adj)
N=852
Edox 15
(Dose Adj)
N=887
Edox 30
n=2189
Edox 30
n=2215n=2298
Drug Assigned During
Double-Blind Phase
Transitioned To
Open-Label VKA
Open-Label NOAC
9,304 (68.2%)
4,258 (31.2%)
Transition Kit
Frequent INR
Testing
Edoxaban*
High-Dose
N=4526
Edoxaban*
Low-Dose
N=4613
FIGURE 1 End-of-Trial Transition to Open-Label Anticoagulation
*There were 12, 11, and 10 patients who transitioned to antiplatelet therapy alone in the warfarin, edoxaban high-dose, and edoxaban low-dose
groups, respectively. There were 16, 20, and 11 patients who transitioned to no antithrombotic therapy in the warfarin, edoxaban high-dose,
and edoxaban low-dose groups, respectively. Frequent international normalized ratio (INR) testing ¼ at least 3 INR tests performed in days 4 to
14 during the transition phase with continued INR testing days 15 to 30 if vitamin K antagonist (VKA) dose changes or if INR was not in the
therapeutic range (2.0 to 3.0). FXa ¼ activated factor X.
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Warfarin 7 Strokes (6 Isch, 1 Hem)
7 Strokes (6 Isch, 1 Hem) HR 1.00 p=0.99
HR 0.98 p=0.967 Strokes (6 Isch, 1 Hem)
Edoxaban High-Dose (N=4,526)
Edoxaban HD
Edoxaban LD
Edoxaban Low-Dose (N=4,613)
7
6
5
4
3
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FIGURE 2 Stroke or SEE
Occurrence of stroke or systemic embolic during the 30-day transition period at the end
of the trial. HD ¼ high dose; Hem ¼ hemorrhagic; HR ¼ hazard ratio; Isch ¼ ischemic;
LD ¼ low dose; SEE ¼ systemic embolic event.
J A C C V O L . 6 4 , N O . 6 , 2 0 1 4 Ruff et al.
A U G U S T 1 2 , 2 0 1 4 : 5 7 6 – 8 4 Transition Plan at End of Anticoagulation Trial
579given as numbers and percentages, medians with 25th
and 75th percentiles, or means with standard de-
viations. Events that occurred between the end-
of-trial visit of double-blind therapy and 30 days later
were included in this analysis. Event rates were
expressed per 100 patient-years. To determine if there
was an increase in bleeding during the period when
the transition kit and open-label VKA were given
together, rates of major bleeding in the 3 treatment
arms were compared from days 1 to 14 in addition
to days 1 to 30. The independent clinical endpoint
committee, which was unaware of randomized treat-
ment assignment, adjudicated all events.
Outcomes included all-cause stroke or SEE, ische-
mic stroke, hemorrhagic stroke, all-cause mortality,
major bleeding (deﬁned by the International Society
on Thrombosis and Haemostasis) (18), and intra-
cranial hemorrhage. Hazard ratios for edoxaban
and warfarin with 95% conﬁdence intervals were
determined using Cox proportional hazards models
with treatment as the only covariate. Cumulative
incidence curves for the attainment of a therapeutic
INR $2.0 were constructed using the Kaplan-Meier
approach and compared using the log-rank test. All
analyses were performed with Stata version 12.1
(Stata Corp., College Station, Texas).RESULTS
Of the 21,105 patients randomized into the ENGAGE
AF–TIMI 48 trial, 13,642 (65%) were alive and still
taking the blinded study drug at their end-of-
trial visit. Baseline characteristics of all patients
TABLE 2 Efﬁcacy and Safety Outcomes
Outcome
Warfarin
Edoxaban
High Dose
Edoxaban High Dose
Vs. Warfarin
Edoxaban
Low Dose
Edoxaban Low Dose
Vs. Warfarinn %/yr n %/yr n %/yr
(n ¼ 4,503) (n ¼ 4,526) HR (95% CI) p Value (n ¼ 4,613) HR (95% CI) p Value
All patients
Stroke/SEE 7 1.90 7* 1.89 1.00 (0.35–2.84) 0.99 7 1.85 0.98 (0.34–2.78) 0.96
Ischemic stroke 6 1.62 6 1.62 0.99 (0.32–3.08) 0.99 6 1.59 0.98 (0.31–3.03) 0.97
Hemorrhagic stroke 1 0.27 1 0.27 0.99 (0.06–15.91) 0.99 1 0.26 0.98 (0.06–15.61) 0.99
Major bleed 11 2.98 10† 2.69 0.90 (0.38–2.13) 0.82 18 4.76 1.60 (0.75–3.38) 0.22
ICH 2 0.54 1 0.27 0.50 (0.05–5.49) 0.56 2 0.53 0.98 (0.14–6.93) 0.98
All-cause mortality 7 1.89 8‡ 2.15 1.14 (0.41–3.14) 0.80 10§ 2.64 1.39 (0.53–3.66) 0.50
(n ¼ 3,147) (n ¼ 3,050) (n ¼ 3,107)
Transitioned to VKA
Stroke/SEE 5 1.94 4 1.60 0.83 (0.22–3.07) 0.78 4 1.57 0.81 (0.22–3.02) 0.75
Major bleed 7 2.71 7 2.80 1.03 (0.36–2.94) 0.95 10 3.93 1.45 (0.55–3.80) 0.45
All-cause mortality 5 1.94 5 2.00 1.03 (0.30–3.56) 0.96 7 2.74 1.42 (0.45–4.47) 0.55
(n ¼ 1,328) (n ¼ 1,445) (n ¼ 1,485)
Transitioned to NOAC
Stroke/SEE 2 1.84 2 1.69 0.92 (0.13–6.52) 0.93 3 2.46 1.34 (0.22–8.03) 0.75
Major bleed 4 3.68 2 1.69 0.46 (0.08–2.51) 0.36 8 6.57 1.79 (0.54–5.93) 0.34
All-cause mortality 2 1.84 2 1.69 0.92 (0.13–6.52) 0.93 2 1.64 0.89 (0.13–6.34) 0.91
*1 patient transitioned to no antithrombotic agent had an ischemic stroke. †1 patient transitioned to antiplatelet therapy had a major bleed. ‡1 patient transitioned to no
antithrombotic agent died. §One patient transitioned to no antithrombotic agent died.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; ICH ¼ intracranial hemorrhage; NOAC ¼ new oral anticoagulant; SEE ¼ systemic embolic event; VKA ¼ vitamin K
antagonist.
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580randomized and those on the blinded study drug
(warfarin or edoxaban) at the end of the trial are
shown in Table 1. Patients completing the trial on
the blinded study drug were slightly younger and
less likely to have received a reduced dose of the6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 To
tal
11 Major Bleeds
10 Major Bleeds
18 Major Bleeds
6 Major Bleeds
4 Major Bleeds
5 Major Bleeds
HR 0.90 p=0.82
HR 1.60 p=0.22
Warfarin (N=4, 503)
Edoxaban High-Dose (N=4,526)
Edoxaban Low-Dose (N=4,613)
ransition Kit
Days after End of Trial Visit
g Events
bleeding during the 30-day transition period at the end of the trial.
igure 2.blinded study drug. Characteristics were balanced
between treatment groups in patients on the study
drug at the end of the trial.
TRANSITION: ALL PATIENTS. At the end of the trial,
9,304 (68.2%) of the 13,642 patients on the blinded
study drug were transitioned to open-label VKA
(Fig. 1). Of these, 6,702 (72%) had not been on a
reduced dose of edoxaban or matching placebo at
the end of the trial and were allocated to 30 mg
edoxaban or matching placebo, in addition to main-
tenance dose, open-label VKA. The remaining 2,579
(27.7%) patients had been on a reduced dose of study
drug and received a transition kit that contained
15 mg edoxaban or matching placebo. There were
4,258 (31.2%) patients who were transitioned to an
open-label NOAC with a nearly even distribution be-
tween dabigatran (n ¼ 2,140) and 1 of the 2 factor
Xa inhibitors (rivaroxaban or apixaban) (n ¼ 2,118).
There were 80 patients (0.6%) who were transitioned
to antiplatelet (n ¼ 33) or no antithrombotic therapy
(n ¼ 47).
Figure 2 shows the distribution of the 21 strokes
that occurred during the 30 days after the end
of the trial (there were no SEEs). The strokes
were evenly distributed across the 3 randomized
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 1920 21 22 23 24 2526 27 282930
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Days after End of Trial Visit
Warfarin (N=4, 503)
Edoxaban High Dose (N=4,526)
Edoxaban Low Dose (N=4,613)
Warfarin
Edoxaban HD
Edoxaban LD
96.6
84.9
85.8
99.4
98.7
98.9
Day 14 Day 30
% Patients with INR ≥2
Median Time to INR ≥2 = 9 days
FIGURE 4 Cumulative Proportion of Patients Transitioned to Open-Label Vitamin K
Anticoagulant With at Least 1 INR $2 Within 30 Days From End of Study
The X at day 0 represents the percentage of patients with an international normalized ratio
(INR)$2 at the end-of-trial visit. Patients initially assigned edoxaban, who did not yet have
an INR measured after the end-of-trial visit were assumed to have an INR <2.0 during the
days between the last study visit and the ﬁrst post-study INR measurement on day 4 or
later. Abbreviations as in Figure 2.
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581treatment arms: warfarin 7 events (1.90%/year),
edoxaban high dose 7 events (1.89%/year), and
edoxaban low dose 7 events (1.85%/year) (Table 2).
Six of the 7 strokes in each group were ischemic.
Major bleeding was also similar across the 3 random-
ized treatment arms during the 30-day end-of-study
transition period (Fig. 3): warfarin 11 events (2.98%/
year), edoxaban high dose 10 events (2.69%/year), and
edoxaban low dose 18 events (4.76%/year) (Table 2).
Major bleeding was also similar from days 1 to 14 when
a transition kit and open-label VKA were given
together (warfarin 6 events, edoxaban high dose 4
events, edoxaban low dose 5 events) (Fig. 3). During
the 30-day period after the end of the study, there
were 25 deaths balanced across the 3 treatment
arms: warfarin 7 (1.89%/year), edoxaban high dose 8
(2.15%/year), edoxaban low dose 10 (2.64%/year)
(Table 2).
TRANSITION OF PATIENTS TO OPEN-LABEL VKA.
The results were consistent regardless of the open-
label anticoagulant selected for transition (Table 2).
Patients transitioned to an open-label VKA had
similar rates across the 3 randomized treatment
arms of stroke (warfarin 5 events [1.94%/year],
edoxaban high dose 4 events [1.60%/year], edox-
aban low dose 4 events [1.57%/year]), bleeding
(warfarin 7 events [2.71%/year], edoxaban high dose
7 events [2.80%/year], edoxaban low dose 10 events
[3.93%/year]), and all-cause mortality (warfarin 5
events [1.94%/year], edoxaban high dose 5 events
[2.00%/year], edoxaban low dose 7 events [2.74%/
year]).
The cumulative proportions of patients with at
least 1 INR $2 in the ﬁrst 30 days post-transition to
open-label VKA are shown in Figure 4. In patients
transitioned to an open-label VKA, 99.4%, 98.7%,
and 98.9% of patients had at least 1 INR $2 in the
warfarin, edoxaban high- and low-dose groups, re-
spectively, by day 30 after the end of the study. By
day 14, the last potential day of transition kit use,
96.6%, 84.9%, and 85.8% of patients had at least 1
INR $2 in the warfarin, edoxaban high-dose, and low-
dose groups, respectively. The median time to an
INR $2 was 9 days (interquartile range: 7 to 12 days) in
the high- and low-dose edoxaban groups. In the
warfarin group, 83% of patients had an INR $2 at the
start of the transition.
TRANSITION OF PATIENTS TO OPEN-LABEL NOAC.
In the 4,258 (31.2%) patients transitioned to NOACs,
there were no signiﬁcant differences in the rates of
stroke for patients in the 3 groups: warfarin 2 events
(1.84%/year), edoxaban high-dose 2 events (1.69%/
year), edoxaban low-dose 3 events (2.46%/year)(Table 2). There were similar rates of major bleeding
(warfarin 4 events [3.68%/year], edoxaban high-dose
2 events [1.69%/year], edoxaban low-dose 8 events
[6.57%/year], and all-cause mortality (warfarin 2
events [1.84%/year], edoxaban high dose 2 events
[1.69%/year], edoxaban low dose 2 events [1.64%/
year]) across the 3 treatment groups.DISCUSSION
Warfarin and other VKAs were the only oral anti-
coagulants available for stroke prevention for more
than a half a century. Since 2009, NOACs have been
demonstrated to be at least as effective and safe as
warfarin in 4 large phase 3 trials in patients with
AF, (7–10), but an excess of both thrombotic and
bleeding events occurred in patients randomized
to NOACs in the 2 previous trials, ROCKET AF (11)
and ARISTOTLE (12), that reported outcomes in
the month following the end of the trial as patients
were transitioned to open-label VKA. Learning
from these experiences, we developed a transition
plan for the ENGAGE AF–TIMI 48 trial, which pro-
tected patients from excess stroke and bleeding
as they were transitioned from warfarin or edox-
aban to 1 of 3 open-label anticoagulants (Central
Illustration).
The most likely explanation for the excess of
ischemic events observed in earlier trials is the delay
Transition PeroidDouble-Blind
       Phase
Solution =
Transition Plan
Edoxaban
Increased Risk
of Ischemic Stroke Components:
1. Open-Label OAC
2. Transition Kit
3. Frequent INRs
Long
Short
Increased Risk 
of Ischemic Stroke
Warfarin
CENTRAL ILLUSTRATION Key Components of the End-of-Trial
Transition
At the end of 2 previous trials, an excess of stroke and bleeding was
observed in patients with AF randomized to a new oral anticoagulant
(NOAC) who transitioned to a vitamin K antagonist (VKA). In the ENAGE
AF-TIMI 48 trial, a transition plan was developed to protect patients
transitioning to open-label VKA or an NOAC at the trial’s end by minimizing
both the risk of ischemic stroke due to inadequate anticoagulation and
the risk of bleeding with excessive anticoagulation while maintaining
the integrity of the blinding to the treatment allocation. The end-of-trial
transition plan consisted of 4 key components: 1) selection of the oral
anticoagulant (VKA or an NOAC) by the treating physician and patient;
2) a 14-day transition kit of modiﬁed-dose edoxaban for patients ran-
domized to edoxaban or matching placebo for patients randomized to
warfarin; 3) early and frequent international normalized ratio (INR)
testing ($3 tests during the ﬁrst 2 weeks); and 4) use of a VKA titration
algorithm.
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582in achieving a therapeutic INR in patients who had
been randomized to an NOAC and who were then
transitioned to an open-label VKA, compared with
patients who had been randomized to warfarin and
who were then transitioned to open-label VKA.
When patients discontinue anticoagulant therapy,
the risk of stroke rises once the anticoagulant effect
wears off: in 24 to 48 h with NOACs and in 3 to 5
days with warfarin. In the case of 2 prior trials with
factor Xa inhibitors (11,12) at the end of the
trial when study medication was discontinued, a
majority of the patients randomized to warfarin had
a therapeutic INR. The lapse in therapeutic anti-
coagulation levels was greater in patients tran-
sitioning from an NOAC to an open-label VKA
before they achieved a therapeutic INR than pa-
tients who were transitioned from warfarin to
open-label VKA. In the ROCKET AF trial, the
median time to ﬁrst therapeutic INR $2 on open-
label VKA was 13 days in the rivaroxaban group
(11). By 30 days after the end of the trial, 83% of
the warfarin group had $1 therapeutic INR valuecompared with only 52% of the rivaroxaban
group. The 2-day transition period with apixaban/
matching placebo in the ARISTOTLE trial was
likely too short in patients transitioning from
apixaban to open-label VKA to cover the period
while the INR was subtherapeutic (INR data not
published) (12).
The end-of-trial transition plan for the ENGAGE
AF–TIMI 48 trial addressed several of the limitations
that arose in prior studies. The period of overlap
with edoxaban/matching placebo transition kit was
extended up to 14 days, so that patients who had
been randomized to edoxaban would have a sufﬁ-
cient period of full anticoagulant protection with
edoxaban while their dose of open-label VKA was
titrated to achieve a therapeutic INR. But this is
helpful only if patients achieve a therapeutic INR
within 2 weeks. A critical feature of the ENGAGE AF–
TIMI 48 transition plan was early and frequent INR
testing with use of a dose titration algorithm to
ensure that the majority of patients randomized to
open-label VKA achieved a therapeutic INR before
lapse of their coverage with the transition kit. We
believe that aggressive and standardized guidance to
promote rapid titration of VKA dose to achieve a
therapeutic level enabled 85% of patients random-
ized to edoxaban and transitioned to open-label VKA
to achieve at least 1 therapeutic INR within 14 days
after the end of the trial and w99% by day 30. The
ROCKET AF investigators provide additional evi-
dence supporting the importance of frequent INR
testing. Physicians managed patients using local
standards, and the number of INR measurements
during the transition was variable. Geographic re-
gions with more frequent INR monitoring had fewer
events (11).
Aggressive monitoring and titration of VKA ther-
apy is also critical to protect patients from the com-
plications of serious bleeding. The transition strategy
in the ENGAGE AF–TIMI 48 trial protected patients
from the excess bleeding that was observed in the
earlier trials even though anticoagulation with an
edoxaban transition kit overlapped with open-label
VKA extended for up to 14 days. The dose modiﬁ-
cation in the transition kit (30 mg once daily for
patients who had not been dose reduced at the
end-of-trial visit and 15 mg once daily for patients
who had been dose reduced at the end-of-trial visit,
regardless of randomized drug assignment) likely
helped mitigate the bleeding risk with overlapping
anticoagulation. Whether simply continuing all pa-
tients on the dose of edoxaban they were on during
the trial would have resulted in an excess of bleeding
is unknown.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: AF predisposes
patients to an increased risk of embolic stroke. Warfarin and
other VKAs are highly effective in preventing stroke, but limited
by their narrow therapeutic window and the inconveniences
imposed by the need for coagulation monitoring and frequent
dose adjustments.
COMPETENCY IN MEDICAL KNOWLEDGE 2: Four NOACs
that inhibit thrombin (factor II) or activated factor X (factor Xa)
are at least as effective and safe as warfarin for preventing stroke
in patients with AF but at the end of previous double-blind
randomized trials of NOACs there was an excess of both stroke
and bleeding events when patients were transitioned to open-
label anticoagulation.
COMPETENCY IN PATIENT CARE: Transitioning from 1
anticoagulant to another is a high-risk period for patients. The
transition plan in the ENGAGE AF–TIMI 48 trial minimized the
risks of stroke due to inadequate anticoagulation and bleeding
from excessive anticoagulation during this critical period,
providing reassurance that patients can be safely transitioned
between oral anticoagulants.
TRANSLATIONAL OUTLOOK: More research is needed to
determine the optimum strategies and guidance for patients who
must change from 1 anticoagulant to another before and after
procedures, when side effects occur, changes in insurance
coverage require selection of an alternative drug or other clinical
developments force therapeutic adjustment.
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sitioning to open-label VKA, 4,258 patients were
transitioned to an open-label NOAC from both war-
farin (n ¼ 1,328) and edoxaban (n ¼ 2,930). There was
no excess of stroke or bleeding observed, reassuring
both clinicians and patients that the transition to an
NOAC can be accomplished safely.
VKAs are effective as long as a therapeutic INR
can be rapidly reached and maintained. Results of
our analyses support that structured and standard-
ized guidance accompanied by frequent monitoring
are required for VKAs to fulﬁll their promise, which
is protection against ischemic events while mini-
mizing the risk of serious bleeding. The challenge in
achieving this balance with the resources available in
routine clinical practice has limited our ability to
improve the adoption and compliance of VKAs in
the expanding population of patients with AF at risk
for stroke.
CONCLUSIONS
The transition plan in the ENGAGE AF–TIMI 48 trial
protected patients from an excess of thrombotic and
bleeding events, and its use may provide reas-
surance that in clinical practice patients can be
safely transitioned between a broad range of oral
anticoagulants.
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